Loeb & Loeb LLP is proud to be a sponsor of the American Conference Institute's (ACI) 3rd West Coast Edition Paragraph IV Disputes Conference, where partners Mark E. Waddell and Adam G. Kelly will speak on panels.
From the conference website:
At ACI's 3nd Annual West Coast edition of its acclaimed Paragraph IV Disputes conference, an experienced faculty of renowned litigators and judges will guide you through every stage of a Paragraph IV challenge. They will help you formulate the offensive moves and defensive plays for the next round in the no-holds barred fight for pharmaceutical product market share. Delegates will have access to the expertise of trial leading patent counsel from generic and branded companies. They will also have the opportunity to hear from judges who have experienced the intricacies of Hatch Waxman litigation first hand. Featuring an up-to-the-minute analysis of the latest game-changing case law developments regarding inequitable conduct, inducement of infringement and the standard of invalidity, this conference will give our attendees the strategies they need to help both brand name and generic companies protect market share and ultimately profits.
Selected Agenda
Tuesday, December 4, 2012
10:30AM - 12:00PM - Prior Art Obviousness and Obviousness-Type Double Patenting
Panelists will explore the reaffirmation of KSR through In re Kao (Fed. Cir. 2011) and discuss practical applications for brand names and generics, including strategies for invoking and responding to an obviousness challenge in concurrence with current law and using the same expert for both infringement and invalidity opinions.
Speakers:
Karen Brown, Ironwood Pharmaceuticals
Meg Snowden, Impax Pharmaceuticals
Mark E. Waddell, Loeb & Loeb LLP
Wednesday, December 5, 2012
11:00AM - 12:45PM - Controversies Surrounding Damages and Injunctions Relative to At Risk Launches
This panel will discuss various issues surrounding injunctions, including inconsistencies between the Federal Circuit and the Supreme Court relative to the granting of a preliminary injunction, practical strategies for brand names and generics in dealing with this discord before the District Courts and Federal Circuit, and the benefits of a stipulated injunction.
Speakers:
Kenneth L. Dorsney, Morris James
Mark T. Jansen, Crowell & Moring
Adam G. Kelly, Loeb & Loeb LLP
T.O. Kong, Wilson Sonsini Goodrich & Rosati
-
Co-Chair, Life Sciences; Chair, Patent Litigation & Counseling